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Objective. To determine whether systemically administered TLR ligands diﬀerentially modulate pulmonary inﬂammation.
Methods. Equipotent doses of LPS (20mg/kg), CpG-ODN (1668-thioat 1nmol/g), or LTA (15mg/kg) were determined via TNF
activity assay. C57BL/6 mice were challenged intraperitoneally. Pulmonary NFκB activation (2h) and gene expression/activity of
key inﬂammatory mediators (4h) were monitored. Results. All TLR ligands induced NFκB. LPS increased the expression of TLR2,
6, and the cytokines IL-1αβ,T N F - α, IL-6, and IL-12p35/p40, CpG-ODN raised TLR6, TNF-α, and IL12p40. LTA had no eﬀect.
Additionally, LPS increased the chemokines MIP-1α/β, MIP-2, TCA-3, eotaxin, and IP-10, while CpG-ODN and LTA did not.
Myeloperoxidase activity was highest after LPS stimulation. MMP1, 3, 8, and 9 were upregulated by LPS, MMP2, 8 by CpG-ODN
and MMP2 and 9 by LTA. TIMPs were induced only by LPS. MMP-2/-9 induction correlated with their zymographic activities.
Conclusion. Pulmonary susceptibility to systemic inﬂammation was highest after LPS, intermediate after CpG-ODN, and lowest
after LTA challenge.
1.Introduction
Severe sepsis is still the leading cause of death in surgi-
cal intensive care units and can be held responsible for
approximately 9% of deaths per year in USA and Germany
[1]. In the course of ongoing sepsis, many organs develop
dysfunction. In this context, the lung can either be the source
of infection or is remotely aﬀected by systemic inﬂammation
as bacterial degradation products reach this organ via the
bloodstream. In both cases, an extensive release of proin-
ﬂammatory cytokines and chemokines induces migration of
neutrophils, ﬁbroproliferation, and reorganization of lung
tissue [2]. An accompanying disruption of the alveolar-
capillary interface and consecutive leakage of protein-rich
ﬂuidintotheinterstitialandalveolarspacecauseshypoxemia
and reduces lung compliance. Acute lung injury (ALI) or its
severeform,theacuterespiratorydistresssyndrome(ARDS),
constitute clinical manifestations of the pathological process
and develop in 40% of the patients suﬀering from sepsis
[3]. Deaths from ALI or ARDS contribute signiﬁcantly to
mortality and morbidity [4].
Toll-like receptors (TLRs) act as pivotal signalling pro-
teins of the inﬂammatory response during sepsis. They are
activated by bacterial, viral, and fungal products. Gram-
negative bacteria release the TLR4 ligand lipopolysaccharide
(LPS) [5] whereas the cell wall component lipoteichoic
acid (LTA) from gram-positive bacteria is primarily bound
by TLR2 [6]. Both, TLR2 and TLR4 are localized in the
cell membrane while TLR9 is localized in lysosomes and
recognizes bacterial DNA from both gram-positive as well
as gram-negative bacteria. Bacterial DNA contains CpG-
ODN motifs [7], which are unmethylated CG dinucleotides
prevalent in bacterial but not in mammalian DNA [8]. TLRs
are diﬀerentially expressed in many organs including heart
a n dl u n ga sw e l la sv a r i o u sc e l lt y p e s[ 9].
It has been shown that TLRs are involved in a number of
inﬂammatory diseases of the lung, such as allergic asthma
[10], autoimmune lung injury [11], and pneumonia [10].2 Mediators of Inﬂammation
Bacterial components induce the expression of inﬂamma-
tory mediators such as proinﬂammatory cytokines and
chemokines, which are highly relevant for the pathogenesis
ofpulmonary inﬂammation and injury [12–14].Bothattract
and activate immune cells inﬁltrating the lung. Also, during
sepsis, they participate in disrupting the alveolo-capillary
structure, rupture of basal membranes, and interstitial
matrix remodelling. The integrity of the extracellular matrix
(ECM) is controlled by a dynamic equilibrium of synthesis
and local degradation. Matrix metalloproteinases (MMPs)
are the main physiological mediators of ECM degradation,
which are also upregulated under pathological conditions
like pulmonary inﬂammation or sepsis. They are primar-
ily regulated by a class of endogenous inhibitors, tissue
inhibitors of MMPs (TIMPs).
There has been a signiﬁcant gain of knowledge about
the high complexity of organ-speciﬁc TLR signalling in the
lung. This organ exhibits a TLR pattern, which derives in
part from parenchymatous cells as well as from immune
cells like neutrophils. Hence, it may be speculated that the
inﬂammatoryresponsedependsonspeciﬁcTLRstimulation,
and thus, various virulence factors might induce diﬀerent
inﬂammatoryresponses.Itcanbehypothesizedthatdiﬀerent
organs express speciﬁc TLR patterns, which serve their need
in defense against pathogens. An accurate characterization
of TLR expression and signalling as well as the investiga-
tion of consecutively induced inﬂammatory mediators [15]
is essential for understanding a diﬀerential inﬂammatory
response to varying stimuli. It might be the fundament for
developing eﬃcient strategies for diagnosis and treatment
of sepsis. However, the number of studies comparing the
inﬂuence of diﬀerent TLRs in vivo is rare [16]. In particular,
a comparison of ligands for TLR2, -4, and -9 in vivo in the
lung has not yet been performed. Therefore, we analysed the
inﬂuenceofthree diﬀerent TLRligands (LTA,LPS,andCpG-
ODN) on the expression of TLRs, cytokines, chemokines,
MMPs, and TIMPs in the murine lung. Also, the subsequent
activities of MPO, MMP-2, and -9 and the level of TNF-α
protein in pulmonary tissue were investigated. The stimuli
were applied remotely (intraperitoneal, i.p.) to simulate the
progression of sepsis.
2.MaterialandMethods
2.1. LPS, LTA, and CpG-ODN Preparations. Lipopolysaccha-
ride (LPS) was from Escherichia coli (E. coli, 0:111, Sigma
Aldrich Chemie GmbH, Munich, Germany). Lipoteichoic
acid (LTA) was kindly provided by S. Morath, University
of Konstanz, Germany (charge MGM5-10) and prepared
as described before [17]. The LPS contamination of the
LTA preparations was less than 1EU/mg as determined
by the LIMULUS amoebocyte lysate assay (Charles River,
Charleston, SC). An immunostimulatory CpG-ODN (1668
thioat, sequence: GCTAGACGTTAGCGT) was purchased
from Tib-MolBiol (Tib-MolBiol GmbH, Berlin, Germany).
2.2. Experimental Animals. 158 male C57BL/6 mice 12
weeks of age from Charles River (Sulzfeld, Germany) were
incorporated in the study. Mice were housed in pathogen-
freecageswithfreeaccesstowaterandstandardrodentchow.
Mice(n = 3–6/group)weretreatedwithi.p.injectionsofPBS
ordiﬀerentTLRligands,thatis,equipotentdoses(seebelow)
of either LTA (15mg/kg), LPS (20mg/kg), or 1668 thioat
(1nmol/g). PBS administration served as control. 30min
before stimulation with CpG-ODN, mice received 1mg/kg
D-Galactosamine (D-GalN; Roth, Karlsruhe, Germany; in
control experiments D-GalN alone did not induce an
inﬂammatory response; data not shown). At the end of the
experiments, mice were sacriﬁced under anaesthesia with
isoﬂurane 2.5Vol.% (Forene, Abbott GmbH, Wiesbaden,
Germany). The animals were handled according to the
principles of laboratory animal care (NIH publication no.
85-23, revised 1996), and animal procedures were approved
by the local committee for animal care.
2.3. TNF Activity Assay. C57BL/6 mice (n = 3/group)
were stimulated with LPS (20mg/kg i.p., according to
[18]), CpG-ODN (1nmol/g i.p., according to [19]), or LTA
(15mg/kg i.p., according to [20]). To determine potency
of the applied concentrations of the three TLR ligands,
undiluted serum from stimulated mice was tested in vitro on
ﬁbroblast cultures. The test of serum was chosen, as during
a remote inﬂammation virulence factors are transported to
the lung via the blood stream. We used a TNF activity assay
according to a protocol published before [21]. Brieﬂy, 2h
after stimulation, serum was taken, and murine ﬁbroblast
tumor cells were incubated with this serum and stained to
determine viability. Binding of TNF-α and -β to surface
receptors initiates lysis in certain types of cells. The TNF
activity assay employs TNF-sensitive, actinomycin D-treated
murine L929 ﬁbroblasts to quantify TNF activity. Murine
ﬁbroblast tumor cells were grown in RPMI 1640 medium
containing 10% fetal calf serum (FCS), 5mM L-Glutamin,
25mMHEPES,5mMsodiumpyruvate,and100Upenicillin
and streptomycin, respectively. A 96-well plate containing 5
× 104 cells per well was incubated over night in a humidiﬁed
incubator (37◦C, 93% O2,7 %C O 2). Medium was removed
and fresh serum or medium or TNF-α standard (rTNF,
Sigma Aldrich, Munich, Germany) were added. 10μLo f
1:50 diluted actinomycin D (Sigma Aldrich) was given to
each well and incubated over night. After removal of the
supernatant, cells were ﬁxed with 5% formalin for 10min.
Then, wells were washed with PBS. 100μL of 0.05% Crystal
Violet (Sigma Aldrich) in 20% ethanol was added to each
well followed by destaining with tab water, and, ﬁnally,
plates were dried. Absorbance was measured at 590nm after
dilutionofthestainwith100μLmethanolperwell.Increased
staining and absorbance corresponded to increased L929
ﬁbroblast viability and decreased lytic eﬀects of TNF.
2.4. Pulmonary Nuclear and Cytoplasmic Extraction. Pul-
monary protein extracts were prepared using the NE-
PER Nuclear and Cytoplasmic Extraction Reagents (Pierce
Biotechnology, Rockford, IL, USA) according to the manu-
facture’s protocol and as published previously [22]. Brieﬂy,
lung tissue was pulverized on dry ice. The tissue weightMediators of Inﬂammation 3
was determined, and the appropriate amount of CER I (10-
fold excess over the weight of tissue) containing 0.5mg/mL
benzamidine (Roche, Basel, Switzerland), 2μg/mL aprotinin
(Roche), 2μg/mL leupeptin (Roche, Basel, Switzerland), and
0.75mM PMSF (Roche, Basel, Switzerland) was added. The
homogenates were vortexed and incubated for 10min on
ice. CER II was added, incubated again for 1min on ice,
and centrifuged for 5min at 13,200U/min (16,110 × g)
and 4◦C. The supernatant was transferred to a prechilled
tube and used as cytoplasmic fraction for analysis of
zymographic activity. The pellet was resuspended in ice-
cold NER. After vortexing and incubation according to
manufacturer’s protocol, the sample was centrifuged again
for 10min at 16,110 × g. The supernatant was immediately
transferred to prechilled tubes and used as nuclear extract
for determination of NFκB-DNA binding activity. The
protein concentration was assessed by use of a bicinchoninic
acid assay kit (Pierce Biotechnology, Rockford, IL, USA)
according to the manufacturer’s protocol.
2.5. Electrophoretic Mobility Shift Assay. NFκBa c t i v i t yw a s
evaluated by electrophoretic mobility shift assay (EMSA)
2h after stimulation (n = 3/group). Nuclear extracts used
in supershift and competition experiments were harvested
from snap frozen lungs as described above. The NFκB
oligonucleotides (Santa Cruz Biotechnology Inc., Santa Cruz
CA, USA) NFκB: 5 -AGTTGAGGGGACTTTCCCAGGC-3
 
(sc-2505)) were end-labelled with (γ-32P) ATP (Amersham,
Freiburg, Germany).
Binding reactions (25μL total) were performed by
incubating 20μg of nuclear extracts for 30min at room
temperature with 4mM Tris-Cl (pH 7.9), 12mM HEPES,
1mM DTT, 60mM KCl, 10% glycerol, 1mM EDTA, 2mg
poly(dI-dC)-poly(dI-dC), and 20,000cpm of the labelled
NFκB oligonucleotide. The speciﬁcity of the DNA-protein
bindingwasdeterminedbycompetitionwitha50-foldmolar
excess of the unlabeled NFκB. The DNA-protein complexes
were electrophoresed for 2h at 30mA in a 4% polyacry-
lamidegelin0.5%tris-borate-EDTArunningbuﬀer.Thegels
were dried for 1h, exposed overnight to imaging plates, and
scanned with a phosphoimager (FLA3000, Fuji, D¨ usseldorf,
Germany).
2.6. Ribonuclease Protection Assay. Cytokine-, chemokine-,
MMP-, and TIMP mRNA levels (n = 4–6/group) were
analysed with ribonuclease protection assay (RPA) 4h after
stimulation. For RPA, lungs were ﬂash-frozen in liquid
nitrogen and kept at −80◦C. The tissue was homogenized
and total RNA was extracted by guanidinium thiocyanate
method as described elsewhere [23].
The mRNA levels of MMP-1, -2, -3, -8, -9, and TIMPs 1–
4pe r2 0μg RNA sample were analysed with mMMP-1 multi-
probe template set (BD Biosciences Pharmingen, San Diego,
CA, USA). Chemokine mRNA of lymphotactin, RANTES
(regulated on activation and expressed/secreted by T cells),
macrophage inﬂammatory protein (MIP)-1α,M I P - 1 β,M I P -
2, macrophage chemotactic peptide (MCP)-1, T-cell acti-
vation protein (TCA)-3, eotaxin, and interferon-inducible
protein (IP)-10 was detected with mCK-5c multiprobe tem-
plateset(BDBiosciencesPharmingen,SanDiego,CA,USA).
mRNA expression of proinﬂammatory cytokines IL-12p35,
IL-12p40, TNF-α,I L - 1 α,I L - 1 β,I L - 6 ,a n dI F N γ as well as
receptorexpressionofTLR2andTLR4weredeterminedwith
custom-made template sets (BD Biosciences, Heidelberg,
Germany). Signals were quantiﬁed densitometrically with
AIDA software v3.5 (Raytest, Straubenhardt, Germany) and
normalized to ribosomal housekeeping gene L32.
2.7. Real Time – Quantitative PCR. TLR1, -6, and -9 gene
expression (n = 6/group) was determined with RT-qPCR
4h after stimulation. TNF-α mRNA was monitored with
the same technique 0, 2, 4, and 6h after TLR-ligand
application. The TaqMan Gene Expression Assays (Applied
Biosystems,FosterCity CA, USA)formurine TLR1(comm.:
Mm00446095m1), TLR6 (comm.:Mm02529782s1), TLR9
(comm.:Mm00446193 m1), TNF-α (comm.: Mm00443258
m1), and murine GAPDH (comm.:Mm999999915g1) as
housekeeping gene were used. RT-PCR was performed
according to the manufacturer’s protocol.
2.8. Enzyme Linked Immunosorbent Assay. TNF-α protein
expression (n = 4/group) was determined with enzyme
linked immunosorbent assay (ELISA; BD Biosciences, San
Jose, CA, USA) 0, 2, 4, and 6h after stimulation. For
protein isolation, pulmonary tissue was homogenized and
incubated on ice for 5min in 1mL ELISA buﬀer containing
protease inhibitors (Roche, complete mini no. 11836153),
PBS, Triton X-100 (1μL/mL, Sigma Aldrich, Munich, Ger-
many), phenylmethylsulfonyl-ﬂuoride (PMSF, 250mM in
isopropanol, 1μL / m L ,R o c h e ,B a s e l ,S w i t z e r l a n d ) .S a m p l e s
were incubated on ice for 20min, homogenized, and cen-
trifuged 15min at 4◦C and 13,110 × g. The supernatant was
used for measuring intrapulmonary TNF-α protein levels
in a microplate reader (Expert 96, Asys Hitech, Eugendorf,
Austria).
2.9. Zymographic Activity Assay. For zymographic activity
o fp r oa n da c t i v ef o r m so fM M P - 2a n d- 9i nl u n gt i s s u e
(n = 3/group), 60μg protein were mixed with 2x tris-glycine
SDS sample buﬀer, and loaded on 10% polyacrylamide gels
(SDS-PAGE) copolymerized with gelatin (each 0.3mg/mL
type A from porcine skin and type B from bovine skin;
Sigma Aldrich, Munich, Germany). Following 90min of
electrophoresis at 125V, gels were washed with 2.5% Triton
X-100 (Sigma Aldrich) for 3 × 20 min to remove SDS.
Afterwards, gels were incubated for 48h at 37◦Ci nd e v e l -
oping buﬀe r( 5 0 m MT r i sH C l ,0 . 2 MN a C l ,5 m MC a C l 2,
0.02% Brij). Gels were stained using 0.1% (w/v) Brilliant
Blue (Sigma Aldrich) in a mixture of water:methanol:acetic
acid (5:5:1v/v), destained in 45% methanol, and 3% acetic
acidinwater(v/v).Areasofproteaseactivityweredetectedas
transparent bands against blue background. All gelatinolytic
activities reported could be inhibited by addition of EDTA
to incubation buﬀer. Zymograms were scanned, and signals
were quantiﬁed using AIDA software (AIDA Image Analyser,
Raytest GmbH, Straubenhardt, Germany). For comparison,4 Mediators of Inﬂammation
the zymographic activity of the three virulence factors 4h
after stimulation was normalized to their baseline activity
(0h, data not shown).
2.10.DeterminationofMyeloperoxidaseActivityinPulmonary
Tissue. After 4h of TLR ligand stimulation, lungs were taken
and ﬂash frozen in liquid nitrogen (n = 5/group). Tissue
was homogenised on ice in 1mL of 0.5% hexadecyltrimethyl
ammonium bromide (HTAB; H-5882, Sigma) in 50mM
potassium phosphate buﬀer (1mL buﬀer/50mg tissue).
1mL of the homogenate was transferred into a tube and
centrifuged at 5,000rpm for 4min. 7μL of the supernatant
were mixed with 200μL o-dianisidine solution (16,7mg o-
dianisidine (D-3252, Sigma) in 90mL ddH2O, 10mL 50mM
potassium phosphate buﬀer, and 50μL1 %H 2O2). The
change in absorbance with time was continuously recorded
at 450nm using a kinetic microplate reader.
2.11. Statistics. A l lv a l u e sa r ee x p r e s s e da sm e a n s± SEM.
Signiﬁcant diﬀerences among experimental groups of P<
.05 are indicated. One-way ANOVA was used to determine
signiﬁcant diﬀerences in mRNA-expression (n = 4), ELISA
(n = 4), and zymographic assay (n = 3) between the
diﬀerent stimulation groups. When appropriate, Bonferroni
post hoc testing was performed. Statistics were calculated
using Prism 5.0 (GraphPad Software Inc., San Diego, CA,
USA).
3. Results
3.1. TNF Activity. To equilibrate the potency of the diﬀerent
applied TLR ligands a TNF activity assay was applied.
Viability of TNF-sensitive ﬁbroblasts exposed to serum from
animals treated by one of the three TLR ligands dropped
signiﬁcantly in all groups (LTA: 57 ± 13.7%, LPS: 40
± 2.4%, CpG-ODN: 42 ± 5.1%; P<. 05 versus PBS
serum control) 2h after incubation. This indicated a strong
inﬂammatory reaction to all three pathogens. There was
no statistical diﬀerence in viability between the stimulated
groups. We concluded that the applied virulence factors
exhibit equipotency concerning TNF induction.
3.2. NFκBA c t i v i t y . NFκB is an essential transcription factor
of inﬂammatory signalling. Hence, NFκB transcriptional
activation was measured 2h after stimulation with the three
TLR ligands using an EMSA. All virulence factors increased
the activity of the transcription factor compared to baseline.
No major visual diﬀerences were revealed following LPS and
CpG-ODN stimulation (Figure 1). LTA, however, induced a
markedly lower NFκB activity than the other two ligands.
3.3. TLR mRNA Expression. Sensitivity of pulmonary tissue
to LPS, CpG-ODN and LTA may be regulated by the level
of speciﬁc TLR expression. Therefore, we monitored mRNA
expression of TLR1, 2, 4, 6, and 9 4h after stimulation.
LTA application resulted in a twofold increase of TLR1, 2,
and 6 expression but did not reach the level of signiﬁcance
(Figure 2), neither TLR4 nor TLR9 mRNA was changed.
PBS LTA LPS CpG ODN
Figure 1: NFκB activation. Representative EMSA for pulmonary
nuclear NFκB activity in LTA-, LPS- and CpG-ODN-stimulated
mice (n = 3/group) after 2h. Each lane represents an individual
animal. LPS induced the strongest signal followed by CpG-ODN
and LTA.
Table 1: TNF-α expression in the lung. Pulmonary TNF-α mRNA
(RQ TNF-a/GAPDH cDNA) and TNF-α protein (pg/mg protein)
expression 0, 2, 4, and 6h after LTA-, LPS-, and CpG-ODN-
stimulation. Signiﬁcant diﬀerences to control values are indicated
(n = 4; ∗P<. 05; bdl = below detection limit;M± SEM; n =
6/group).
TNF-α mRNA (RQ
TNF-α/GAPDH cDNA)
TNF-α protein
(pg/mg protein)
0hL T A 1.11± 0.11 0.00 ± 0.00 (bdl)
2hL T A 5.79± 0.68∗ 16.05 ± 7.89∗
4hL T A 2.08± 0.36 0.00 ± 0.00 (bdl)
6hL T A 1.72± 0.37 0.00 ± 0.00 (bdl)
0h LPS 0.61 ± 0.07 0.00 ± 0.00 (bdl)
2h LPS 14.31 ± 1.36∗ 24.36 ± 3.63∗
4h LPS 12.82 ± 2.05∗ 12.35 ± 2.74∗
6h LPS 12.70 ± 1.05∗ 9.78 ± 0.42∗
0hCpG 0.54± 0.02 0.00 ± 0.00 (bdl)
2h CpG 19.88 ± 3.90∗ 12.81 ± 1.55∗
4hCpG 2.65± 0.67 2.70 ± 0.84
6hCpG 2.74± 0.71 3.84 ± 2.92
LPS acted more strongly elevating TLR2 and 6 expressions
signiﬁcantly versus control and TLR4 versus LTA-treated
animals. CpG-ODN raised TLR6 mRNA exclusively.
3.4. Time Course of TNF-α mRNA and Protein Expression.
TNF-α has been shown to be an early inﬂammatory marker,
which is often upregulated transiently [24]. Therefore, we
monitored the time course of pulmonary TNF-α mRNA
expression 0, 2, 4, and 6h after virulence factor challenge
(Table 1, n = 4/group). TNF-α mRNA was signiﬁcantly
induced 2h after LTA and CpG-ODN. LPS challenge, how-
ever, raised mRNA expression signiﬁcantly at all investigated
time points. Under baseline conditions, TNF-α protein
expressionwasnotdetectableinELISA.2hafterstimulation,
all virulence factors signiﬁcantly increased TNF-α protein
expression (Table 1). At the later time points, a signiﬁcant
enhancement of TNF-α protein was observed in the LPS
group only.Mediators of Inﬂammation 5
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Figure 2: TLR mRNA expression. Analysis of TLR1, 2, 4, 6, and 9 in control, LTA-, LPS-, and CpG-ODN-stimulated pulmonary tissue
(TLR1/6/9 detected with RT-qPCR, values depicted as relative quotient (RQ) to housekeeping gene; TLR2/4 detected with RPA, values
expressed as arbitrary units (AU) normalized to L32 mRNA,). Alphabetic characters indicate P-values <. 05 from Bonferroni post hoc
testing (a = versus control, b = versus LTA, c = versus CpG-ODN; M ± SEM; n = 6/group).
3.5.CytokineandChemokinemRNAExpression. Theamount
of cytokine and chemokine mRNA expression reﬂects the
severity of inﬂammation. Therefore, these mediators were
investigated in the lung 4h after stimulation using RPA
(Figure 3). LTA stimulation did not signiﬁcantly induce any
cytokine mRNA expression. In contrast, LPS stimulation
induced a signiﬁcant increase of all tested cytokines IL-1α,
IL-1β,T N F - α, IL-6, IL-12p35, IL-12p40, and IFN-γ,w h e r e a s
CpG-ODN only elevated TNF-α and IL-12p40 mRNA.
Analysis of lungs from LPS-treated mice revealed a
markedandsigniﬁcantincreaseinallmonitoredchemokines
(lymphotactin, RANTES, MCP-1, MIP-1α,M I P - 1 β, MIP-2,
TCA-3, eotaxin and IP-10, Figure 4) as compared to all other
groups. However, neither LTA nor CpG-ODN stimulation
caused any signiﬁcant changes in chemokines.
3.6. Myeloperoxidase Activity in Pulmonary Tissue. Myelop-
eroxidase (MPO) activity was assayed as a marker of
neutrophil inﬁltration into the lung. MPO activity was
increased 9- to 16-fold in all stimulated groups 4h after
TLR ligand application (Figure 5). With a 16-fold induction
compared to the control group, MPO activation was highest
in lung tissue from LPS-treated mice. This value diﬀered
signiﬁcantly from LTA- and CpG-stimulated mice which
showed a 9- and 11-fold increase. Interestingly, doubling
of the standard LTA dose did not further raise MPO
activity.
3.7. MMP and TIMP mRNA Expression. During inﬂam-
mation extracellular matrix remodelling may occur. The
presenceofMMPsandTIMPsindicatescurrentmodiﬁcation
of lung tissue. Consequently, 4h after simulation total MMP
mRNA expression was signiﬁcantly enhanced by all three
virulence factors with the greatest overall stimulus being
CpG-ODN (Figure 6). LTA induced a signiﬁcant increase
in MMP-2 and MMP-9 as well as a 5-fold elevation in
MMP-3 and 18-fold elevation in MMP-8. LPS stimulation
signiﬁcantlyenhancedMMP-1,MMP-3,MMP-8,andMMP-
9 while CpG-ODN raised MMP-2 and MMP-8 signiﬁcantly
as well as MMP-1, MMP-3, and MMP-9 nonsigniﬁcantly.6 Mediators of Inﬂammation
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Figure 3: Cytokine mRNA expression. Densitometric analysis of IL-1α,I L - 1 β,T N F - α, IL-6, IL-12p35, IL-12p40, and IFN-γ in control,
LTA-, LPS-, and CpG-ODN-stimulated pulmonary tissue. Values of mRNA expressions are normalized to L32 and expressed as arbitrary
units (AU). Alphabetic characters indicate P-values <. 05 from Bonferroni post hoc testing (a = versus control, b = versus LTA, c = versus
CpG-ODN; n = 4; M ± SEM; n = 6/group).
Furthermore, LPS signiﬁcantly enhanced TIMP-1 and
-3 expressions whereas LTA and CpG-ODN did not induce
any changes in single TIMP expressions. Interestingly, the
unchanged TIMP-2 expression was relatively high in all
groups (control: 57.78 ± 14.79; LTA: 57.08 ± 2.63; LPS:
25.38 ± 1.68; CpG-ODN: 42.56 ± 2.80) compared to
TIMP-1 and -3.
Since the stoichiometry between the gene expression of
MMPs and their physiological antagonist (TIMPs) has been
shown to be important for the regulation of the extracellularMediators of Inﬂammation 7
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Figure 4: Chemokine mRNA expression. Densitometric analysis of MIP-1α, MIP-1β, MIP-2, TCA-3, eotaxin, and IP-10 in control, LTA-,
LPS-, and CpG-ODN-stimulated pulmonary tissue. Values of mRNA expressions are normalized to L32 and expressed as arbitrary units
(AU). Alphabetic characters indicate P-values <. 05 from Bonferroni post-hoc testing (a = versus control, b = versus LTA, c = versus CpG-
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Figure 5: Myeloperoxidase activity in pulmonary tissue. Level of
myeloperoxidase activity (x-fold of control) in lung tissue from
control,LTA-,LPS-orCpG-treatedmice4hafterstimulation(∗P<
.01 versus control, #P<. 01 versus LPS; M ± SEM; n = 5/group).
matrix remodelling, we calculated the ratios of MMPs to
TIMPs (Table 2). Due to the up-regulation of the total
MMP mRNA expression in all stimulated groups, overall
MMP/TIMP ratio was signiﬁcantly elevated 4-fold by LTA,
5-fold by LPS, and 8-fold by CpG-ODN.
3.8. Zymographic Activity of MMP-2 and MMP-9. To expand
the results on MMP and TIMP mRNA expression, the activ-
ity of MMP-2 and MMP-9 was detected in a zymographic
assay. Accordingly, we detected an induction of MMP-2
and MMP-9 in their precursory (pro) and active form (not
shown). To compare eﬀects of diﬀerent virulence factors, we
normalized zymographic activity (4h) to baseline activity
(0h) (Figure 7). CpG-ODN challenge signiﬁcantly increased
MMP-2 activity compared to LPS and LTA application. Here,
up-regulation was mainly due to 72kDa proMMP-2 activity.
MMP-9 activity was enhanced comparably by all stimuli.
4. Discussion
With the present study, we characterized diﬀerential pul-
monaryinﬂammatoryresponsestovariousvirulencefactors.
Studies comparing the inﬂuence of diﬀerent TLR stimuli
on pulmonary tissue were mainly performed in vitro [25].
Therefore, we decided to compare LTA, LPS, and CpG-ODN
challenge using remote stimulation in vivo to simulate the
initiation of sepsis. For characterization of the inﬂammatory
cascade we monitored a variety of endpoints like TLR
expression, NFκB activation, expression of various cytokines
and chemokines, and MPO activity as well as expression of
MMP/TIMPs. In the lung, this broad combination of TLR
stimuli and endpoints detected in vivo has not yet been
performed.
To provide comparability of results, we deﬁned equipo-
tent concentrations for LTA, LPS, and CpG-ODN via a TNF8 Mediators of Inﬂammation
Table 2: MMP/TIMP mRNA ratios. MMP/TIMP mRNA ratios in control, LTA-, LPS- and CpG-stimulated pulmonary tissue. Values of
mRNA expressions are normalized to L32 and expressed as arbitrary units (AU). Alphabetic characters indicate P-values <. 05 from
Bonferroni post-hoc testing (a = versus control, b = versus LTA, c = versus LPS, d = versus CpG-ODN; M ± SEM; n = 4/group).
Control LTA LPS CpG
MMP-l/TIMP-l 0.00 ± 0.00 0.00 ± 0.00 c, d 0.07 ± 0.01 a, b, d 0.06 ± 0.02 b
MMP-2/TIMP-l 2.29 ± 0.13 5.10 ± 0.79 a, c 0.38 ± 0.08 b, d 4.19 ± 0.43 c
MMP-3/TIMP-l 0.22 ± 0.05 0.81 ± 0.20 0.39 ± 0.07 0.95 ± 0.44 a
MMP-8/TIMP-l 0.15 ± 0.02 2.28 ± 0.15 0.55 ± 0.09 d 4.45 ± 1.73 a, c
MMP-9/TIMP-l 0.11 ± 0.04 1.44 ± 0.08 a, c, d 0.12 ± 0.05 b 0.55 ± 0.18 b
MMP-l/TIMP-2 0.00 ± 0.00 0.00 ± 0.00 c 0.09 ± 0.02 a, b, d 0.01 ± 0.00 c
MMP-2/TIMP-2 0.09 ± 0.01 0.24 ± 0.16 d 0.41 ± 0.04 a, b, d 0.48 ± 0.05 a, b, c
MMP-3/TIMP-2 0.00 ± 0.00 0.04 ± 0.01 c 0.48 ± 0.15 a, b, d 0.11 ± 0.02 C
MMP-8/TIMP-2 0.01 ± 0.00 0.11 ± 0.01 c, d 0.60 ± 0.05 a, b 0.48 ± 0.13 a, b
MMP-9/TIMP-2 0.00 ± 0.00 0.07 ± 0.01 0.12 ± 0.04 a 0.06 ± 0.02
MMP-l/TIMP-3 0.00 ± 0.00 0.00 ± 0.00 c 0.04 ± 0.01 a, b, d 0.01 ± 0.00 c
MMP-2/TIMP-3 0.27 ± 0.04 0.70 ± 0.06 a, c 0.26 ± 0.10 b, d 0.64 ± 0.07 a, c
MMP-3/TIMP-3 0.03 ± 0.01 0.11 ± 0.02 0.24 ± 0.05 a 0.14 ± 0.03
MMP-8/TIMP-3 0.02 ± 0.00 0.32 ± 0.00 0.37 ± 0.12 0.61 ± 0.15 a
MMP-9/TIMP-3 0.01 ± 0.01 0.21 ± 0.02 a, d 0.09 ± 0.05 0.08 ± 0.02 b
Total MMP/TIMP 0.08 ± 0.01 0.33 ± 0.01 a, d 0.42 ± 0.08 a 0.60 ± 0.05 a, b
activityassay.TNFinductionasameasureforequipotencyof
inﬂammatory stimuli has been established earlier [25]. After
stimulation with LPS we observed a strong proinﬂammatory
reaction with increased NFκB activation, enhanced cytokine
and chemokine expression, and a diﬀerential response in
MMP and TIMP expression. The equipotent dose of CpG-
ODN initiated mediator expression to a lesser degree. Here,
cytokine and chemokine expression remained a multiple
below values evoked by LPS. Interestingly, stimulation with
an equipotent dose of LTA had a markedly lesser impact on
the induction of cytokines and chemokines in lung tissue.
Signiﬁcant variations only occurred in TNF-α expression,
MPO activity, and MMP/TIMP regulation.
In order to understand the diﬀerential answers to TLR
stimulation better, we investigated the expression of TLR1,
2, 4, 6, and 9. LPS induced an increased expression of
TLR2, 4, and 6 whereas CpG-ODN elevated solely the
TLR6 expression. LTA did not change any investigated TLR.
Induction of TLR2 and 4 by LPS in pulmonary tissue
has already been observed by others [26]. Interestingly,
pulmonary TLR4 mRNA expression did not reveal a strong
regulation after LPS challenge. In contrast, TLR2 expression
was very sensitive to LPS, as it was increased more than
10-fold. In this context, it is interesting that also TLR6
is upregulated by LPS and CpG-ODN challenge, as LTA
signallingdependsonheterodimerizationofTLR2andTLR6
or TLR2 and TLR1, and CD36 [27]. This up-regulation of
TLR2 and TLR6 might sensitize the lung in an ongoing
inﬂammation to gram-positive stimuli. In accordance with
our results, it has been shown that bronchial epithelium
regulates its sensitivity to recognize microbes by managing
TLR expression levels [27]. Bronchial epithelial cells could
be stimulated in vitro only marginally by gram-positive
bacteria bearing known TLR2 ligands or with LTA alone
while gram-negative bacteria were easily recognized. As
mucosal surfaces are prone to contact with pathogenic,
as well as nonpathogenic microbes, immune recognition
principles have to be tightly regulated to avoid uncontrolled
permanent activation. Hence, airway epithelium displays a
low sensitivity to inhaled gram-positive bacteria whereas
gram-negative bacteria, which are rarely found in airways,
do easily induce epithelial activation [27]. A strong immune
response following a ﬁrst hit with LPS and a moderate
induction caused by ﬁrst hit with LTA might be expected
in the lung. However, due to the observed up-regulation
of TLR2 by gram-negative challenge sensitivity to LTA may
be elevated during a second hit. CpG-ODN-dependent-up-
regulation of TLR6 detected here may further support the
sensitizationtoLTAduringongoinginﬂammation.However,
signiﬁcant up-regulation of pulmonary TLR9 expression was
not demonstrated here and is in accordance with recent
results from our group [14].
Cytokine release evoked by TLR stimulation on lung
tissue has been investigated in diﬀerent settings, such as
cultured pulmonal cells or by application of TLR ligands to
the airway side [12, 14]. To our knowledge, this study com-
pares for the ﬁrst time a challenge with diﬀerent TLR ligands
applied systemically. TNF-α taken from the plasma was used
to determine equipotent doses of remote stimuli. On the
other hand, TNF-α mRNA and protein were investigated in
pulmonary tissue to compare the inﬂammatory response of
the lung from 0–6h after stimulation with each TLR-ligand.
Here, LPS led to a signiﬁcant increase of TNF-α mRNA
and protein at all time points while LTA and CpG-ODN
elevated its expression only at the earliest time point (2h).
These results conﬁrm the well-known observation that TNF-
α is an early inﬂammatory marker [24]. Apart from TNF-
α, LPS also induced all other investigated proinﬂammatory
cytokines at 4h, CpG-ODN raised only IL12p40 while LTA
failed to elevate any of the other inﬂammatory markers.Mediators of Inﬂammation 9
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Figure 6: MMP, TIMP mRNA expression. Densitometric analysis of MMP-1, -2, -3, -8, 9, TIMP-1, and -3 in control, LTA-, LPS-, and CpG-
ODN-stimulated pulmonary tissue as well as total MMP and TIMP expression. Values of mRNA expressions are normalized to L32 and
expressed as arbitrary units (AU). Alphabetic characters indicate P-values <. 05 from Bonferroni post-hoc testing (a = versus control, b =
versus LTA, c = versus LPS, d = versus CpG-ODN; M ± SEM; n = 4/group).
These ﬁndings further support the above-mentioned low
sensitivity of the lung to gram-positive stimuli, which may
be overcome by direct intrapulmonary application [28,
29]. We found a signiﬁcant up-regulation of IL-12p40 in
vivo in pulmonary tissue by CpG-ODN and LPS. This
transfers the results from Albrecht et al. [25] to the in
vivo situation, as they demonstrated an induction of IL-
12p40 mainly by CpG-ODN in transfected macrophages and
dendritic cells. IL-12p40 bridges the gap between innate
and adaptive immunity because it is potently regulated in
antigen-presenting cells, thereby activating the adaptive T-
helper (TH1) cells.
These immune cells are attracted into the site of
inﬂammation by chemokines [30]. In our study, signiﬁcant
chemokine induction was only found after LPS stimulation.
This is in accordance with the observed high MPO activity
after TLR4 stimulation, as monocytes and neutrophils
attracted by chemokines exclusively release MPO. LPS-
dependent inﬁltration of polymorphonuclear neutrophils
into pulmonary vasculature, lung interstitium, and alveolar
s p a c ea sw e l la sb r o n c h o a l v e o l a rl a v a g eﬂ u i dh a sa l r e a d y
been demonstrated by others [31]. In our setting of remote
stimulation, CpG-ODN, and LTA failed to raise chemokine
expression.Attheﬁrstglimpse,thisseemstobeincontrastto
the literature [28, 32, 33]. However, this diﬀerence between
our results and those of others may be attributed to the
diverse mode of administration (local versus systemical).
MMPs play a decisive role in the repair of the alveolar
epithelium during pulmonary inﬂammation by cleaving
components of the extracellular matrix (ECM) [34]. How-
ever, excessive expression of MMPs can also destroy the
ECM and initiate further inﬂammation and changes in
pulmonary architecture. MMP-2 and -9 can be produced by
various resident cells in the lung [35] or might stem from
stimulated immune cells. Similar to MMPs, the deﬁned role
oftheirinhibitorsisalsonotfullyunderstoodinsepsis.Some
studies indicate that high TIMP-1 levels are associated with
severe forms of the disease and might, therefore, serve as10 Mediators of Inﬂammation
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Figure 7: MMP zymographic assay. Percentage of total quantiﬁed MMP-2 or MMP-9 activity, respectively. Zymographic activity after
stimulation (4h) was normalized to baseline activity (0h). Values are expressed as arbitrary densitometric units (AU; ∗P< . 05 versus
LTA and LPS; n = 3/group).
possible prognostic markers of poor survival [36]. Despite
low mRNA levels of cytokines and chemokines in the LTA
group, MMP-2 and -9 were signiﬁcantly induced in lung
tissue as a sign of inﬂammatory aﬀection. However, TIMP-
1 expression was low and remained unaﬀected by LTA. A
high MMP9/TIMP1 ratio has been shown to be associated
with a less severe progression of diﬀerent lung diseases [37–
39]. LPS challenge signiﬁcantly elevated TIMP-1 and -3.
As mentioned above, high TIMP-1 expression is associated
with severe lung disease. TIMP-3 may act in a similar
manner as TIMP-3-deﬁcient mice were protected from
sepsis-induced pulmonary inﬂammation and remodelling
[40].
The present study provides detailed information on
inﬂammatory events in the lung after in vivo challenge
with equipotent doses of LTA, LPS, and CpG-ODN in a
murine model of sepsis. These diﬀerent remote stimuli
resulted in speciﬁc inﬂammatory responses in pulmonary
tissue indicating an organ-speciﬁc immune modulation.
LTA induced the lowest number of inﬂammatory medi-
ators, which was associated with a mild progression of
lung remodelling. As gram-positive bacteria are commonly
inhaled,therespectiveimmuneresponseofthelunghastobe
strictlycontrolledtoavoidautodestructiveinﬂammation.On
the other hand, gram-negative bacteria enter the respiratory
t r a c tm u c hm o r er a r e l y ,w h i c hm a ye x p l a i nt h es t r o n g e r
inﬂammatory response to LPS in our setting. However,
an ongoing infection with gram-negative bacteria might
sensitize the lung towards gram-positive stimuli as TLR2 and
TLR6 expressions are upregulated by LPS. In addition, CpG-
ODN that induces the inﬂammatory cascade via TLR9 is
released by both gram-positive and gram-negative bacteria.
Thus, in case of a bacterial sepsis, the inﬂammatory response
in the lung will never be induced by exclusive activation of
TLR2 or TLR4 but always by costimulation of TLR9.
Our ﬁndings indicate that the lung may be more sus-
ceptible to systemic inﬂammation caused by gram-negative
stimuli than to one elicited by gram-positive stimulation.
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